日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs

铁木皂苷AIII通过抑制CAR-Treg细胞增强CAR-T细胞的效力并预防复发。

Hou, Mingqi; Zhang, Wenjun; Qi, Ziping; Li, Guiming; Mei, Husheng; Qi, Shuang; Jin, Rui; Zhao, Yuedong; Tang, Xiaochen; Xiu, Bing; Chen, Xiaotong; Zhao, Yunshuo; Hu, Chen; Qian, Changlin; Li, Xiuchun; Xu, Zhan; Chen, Yongfei; Wu, Chao; Wang, Beilei; Yan, Lejin; Li, Dan; Huang, Yushan; Liang, Rui; Wang, Aoli; Liu, Jing; Wang, Wenchao; Li, Bin; Long, Jun; Li, Ping; Liang, Aibin; Liu, Qingsong; Yang, Jing

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2-Mutant Leukemias

以DESI2为靶点治疗JAK2突变型白血病的新型治疗策略

Mei, Husheng; Wen, Wuqiang; Zhang, Wenjun; Zhang, Shujing; Sun, Ting; Li, Guiming; Zhang, Jing; Qi, Shuang; Zhou, Jie; Li, Bing; Zhao, Yunshuo; Chen, Xiaotong; Li, Bowen; Xue, Yiying; Lu, Wang; Sun, Yanli; Wang, Jingyao; Shan, Hengyue; Zhang, Shengzhe; Huang, Yushan; Chen, Yisa; Wang, Wenchao; Liu, Qingsong; Lu, Wenchao; Tan, Li; Ding, Yi; Fu, Jianfei; Long, Jun; Zhang, Lei; Zhao, Baobing; Liang, Aibin; Jiang, Baishan; Yang, Jing

Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meeting

新型非病毒体内CAR-T疗法:2025年ASH年会最新进展

Xue, Bin; Liu, Yifan; Liang, Aibin; Zhang, Wenjun

Spatially concentrated adenine base editors efficiently correct PLP1 mutations in oligodendrocytes.

空间集中的腺嘌呤碱基编辑器能有效纠正少突胶质细胞中的 PLP1 突变。

Zhang Chi, Ye Ke, Shang Yafang, Song Yixuan, Li Pingping, Jiang Xinyue, Yang Cuiping, Liang Aibin, Zhang Jian, Meng Feilong, Zhang Mingliang

Zanubrutinib-based regimen as the salvage or bridging treatment of CART therapy in relapsed or refractory, non-germinal center B-cell-like diffuse large B-cell lymphoma: a retrospective multicenter cohort study

以泽布替尼为基础的方案作为复发或难治性非生发中心B细胞样弥漫性大B细胞淋巴瘤CAR-T细胞疗法的挽救或桥接治疗:一项回顾性多中心队列研究

Lu, Yan; Ye, Shiguang; Zhou, Lili; Yuan, Xianggui; Li, Ping; Qian, Wenbin; Liang, Aibin

The prognostic utility of a combined PNI-HB immunonutritional index in CD19 CAR T-cell therapy for relapsed/refractory non-Hodgkin lymphoma

PNI-HB联合免疫营养指数在CD19 CAR T细胞疗法治疗复发/难治性非霍奇金淋巴瘤中的预后价值

Liu, Yifan; Chen, Xi; Li, Ping; Hao, Wenjuan; Luo, Xiu; Zhang, Wenjun; Lu, Huina; Xue, Bin; Liang, Aibin

Function-driven design of a surrogate interleukin-2 receptor ligand

基于功能的白细胞介素-2受体配体替代设计

Tang, Ziwei; Cheng, Zelin; Li, Teng; Wang, Fulian; Zhang, Liangminghui; He, Xiuxiu; Liu, Lili; Wang, Wei; Liang, Aibin; Yang, Guang

The predictive value of interleukin-2 receptor and prognostic nutritional index in patients with diffuse large B-cell lymphoma

白细胞介素-2受体和预后营养指数对弥漫性大B细胞淋巴瘤患者的预测价值

Xie, Fengyang; Li, Yulan; Zhu, Xinyu; Zhu, Jingjing; Ma, Xiaoxia; Yan, Dimei; Liang, Aibin; Xiu, Bing

Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed/refractory acute myeloid leukemia

CLL1 CAR-T细胞疗法治疗复发/难治性急性髓系白血病成人患者的最新数据

Zhang, Xiaomei; Lu, Wenyi; Zhang, Wenjun; He, Xiaoyuan; Zhang, Yu; Jin, Xin; Zhang, Meng; Wang, Yingshuai; Guan, Xuwen; Zhang, Rui; Wang, Bing; Lyu, Hairong; Xiao, Xia; Bai, Xue; Pu, Yedi; Meng, Juanxia; Zhu, Haibo; Wang, Zhao; Zhang, Huan; Lyu, Cuicui; Zhang, Hongkai; Liang, Aibin; Zhao, Mingfeng

Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial

作者更正:4-1BB共刺激CD19特异性CAR-NK细胞疗法治疗难治性/复发性大B细胞淋巴瘤的安全性和可行性:一项I期试验

Lei, Wen; Liu, Hui; Deng, Wenhai; Chen, Wei; Liang, Yun; Gao, Wenxia; Yuan, Xianggui; Guo, Shanshan; Li, Ping; Wang, Jinyong; Tong, Xiangmin; Sun, Yi Eve; Liang, Aibin; Qian, Wenbin